Clara Hayn

Dr. Clara Hayn

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ASAnna Seller
Anna Seller
CTChristian M. Tegeler
Christian M. Tegeler
JMJonas Mauermann
Jonas Mauermann
TSTatjana Schreiber
Tatjana Schreiber
IHIlona Hagelstein
Ilona Hagelstein
MMMelanie Märklin
Melanie Märklin
Ligands of the natural killer group 2D (NKG2DL) family are expressed on malignant cells and are usually absent from healthy tissues. Recognition of NKG2DLs such as MICA/B and ULBP1-3 by the activating immunoreceptor NKG2D, expressed by NK and cytotoxic T cells, stimulates anti-tumor immunity in breast cancer. Upregulation of membrane-bound NKG2DLs in breast cancer has been demonstrated by immunohistochemistry. Tumor cells release NKG2DLs via proteolytic cleavage as soluble (s)NKG2DLs, which allows for effective immune escape and is associated with poor prognosis. In this study, we collected serum from 140 breast cancer (BC) and 20 ductal carcinoma in situ (DCIS) patients at the time of initial diagnosis and 20 healthy volunteers (HVs). Serum levels of sNKG2DLs were quantified through the use of ELISA and correlated with clinical data. The analyzed sNKG2DLs were low to absent in HVs and significantly higher in BC patients. For some of the ligands analyzed, higher sNKG2DLs serum levels were associated with the classification of malignant tumor (TNM) stage and grading. Low sMICA serum levels were associated with significantly longer progression-free (PFS) and overall survival (OS). In conclusion, we provide the first insights into sNKG2DLs in BC patients and suggest their potential role in tumor immune escape in breast cancer. Furthermore, our observations suggest that serum sMICA levels may serve as a prognostic parameter in the patients analyzed in this study.

4 July 2024 in Cancers
Verified
Journal Article
Open access
PDF file
SSSylwia A. Stefańczyk
Sylwia A. Stefańczyk
CHClara Hayn
Clara Hayn
JHJonas S. Heitmann
Jonas S. Heitmann
SJSusanne Jung
Susanne Jung
LZLatifa Zekri
Latifa Zekri
MMMelanie Märklin
Melanie Märklin
Despite recent advances in immunophenotyping, the prognosis of acute myeloid leukemia (AML) is still mainly estimated using age and genetic markers. As the genetic heterogeneity of AML patients is high, flow cytometry-based classification with appropriate biomarkers can efficiently complement risk stratification and treatment selection. An increased expression of B7-H3 (CD276), an immune checkpoint protein, has been reported and associated with poor prognosis. However, the available data are limited and heterogeneous. Here, we used a novel, proprietary murine anti-B7-H3 8H8 antibody for the flow cytometric analysis of B7-H3 expression in AML blasts from 77 patients. Our antibody reliably detected substantial B7-H3 expression in 62.3% of AML patients. B7-H3 expression was higher in the monocytic French–American–British (FAB) M5 group and in intermediate and poor risk patients according to the European Leukemia Network. Using receiver operating characteristics (ROCs), we identified a specific fluorescence intensity cut-off of 4.45 to discriminate between B7-H3high and B7-H3low expression. High B7-H3 expression was associated with shorter overall survival (OS) and progression-free survival (PFS). In conclusion, we have developed a novel B7-H3 antibody that serves as a new tool for the detection of B7-H3 expression in AML and may help to facilitate risk stratification and treatment selection in AML patients.

9 February 2026 in The European Physical Journal E
Verified
Journal Article
Open access
PDF file
OVOlga Vasiljevic
Olga Vasiljevic
NHNicolas Harmand
Nicolas Harmand
AHAntoine Hubert
Antoine Hubert
LKLydia Kebbal
Lydia Kebbal
VBVolker Bormuth
Volker Bormuth
LPLea-Laetitia Pontani
Lea-Laetitia Pontani
Mechanical contributions are crucial regulators of diverse biological processes, yet their in vivo measurement remains challenging due to limitations of current techniques that can be destructive or require complex dedicated setups. This study introduces a novel method to synthesize biocompatible, self-functionalizing stress sensors based on inverted emulsions that can be used to probe stresses inside tissues but can also locally perturb the biological environment through specific binder presentation or drug delivery. We engineered an optimal design for these inverted emulsions, focusing on finding the balance between the two contradictory constraints: achieving low surface tension for deformability while maintaining emulsion instability for efficient self-functionalization and drug release. Proof-of-concept experiments in both agarose gels and complex biological systems, including brain organoids and zebrafish embryos, confirm the droplets ability to deform in response to mechanical stress applied within the tissue, to self-functionalize and to release encapsulated molecules locally. These versatile sensors offer a method for noninvasive stress measurements and targeted chemical delivery within living biological tissues, giving the potential to overcome current technical barriers in biophysical studies. Graphical Left 3 panels: Inverted emulsion droplets self-functionalize over time once injected in a biological medium. Right panel: After self-functionalization, the deformability of the droplets allows for the measurment of local stresses.